How many times can one box of Giritinib (Segatan) be taken and the dosage instructions?

Gilitinib is a highly selective FLT3 inhibitor, mainly used to treat patients with relapsed or refractory acute myeloid leukemia (AML), especially those with FLT3 mutations. The drug prevents leukemia cell proliferation and induces apoptosis by inhibiting the abnormal FLT3 signaling pathway. Giritinib is usually taken orally in the form of tablets, mostly in specifications of 40mg or 120mg, which is convenient for patients to take at home for a long time. The dosing schedule is relatively fixed, so the time a box of medicine can be taken depends mainly on the number of tablets in each box and the daily dose.

Among the recommended clinical doses, the standard dose of gilitinib is 120 mg once daily (usually one tablet), which can be taken with or on an empty stomach and is not affected by diet. If a box of medicine is 30 tablets, and the patient takes one tablet every day, then one box can be taken for 30 days, which is the dosage for a complete course of treatment. Some doctors may adjust the dose appropriately based on the patient's specific condition, tolerance and drug blood concentration monitoring results, such as temporarily reducing the dose to 80 mg/day or discontinuing the drug for observation when serious adverse reactions occur. Therefore, patients should strictly follow the doctor's instructions and not change the dosage or interval of medication on their own.

During the medication process, if the patient misses a dose, he should take it as soon as possible. However, if it is close to the next dose time, he should not take an additional dose to avoid excessive blood concentration. Giritinib requires long-term continuous use to maintain its efficacy. Clinical data shows that continuous use can significantly extend overall survival and reduce the risk of disease recurrence. Stopping medication or taking it intermittently may lead to disease relapse or an increased risk of drug resistance. Therefore, it is recommended that patients take medication on time and in sufficient amount, and conduct course management under the guidance of a doctor.

In addition, patients should pay attention to regular blood tests, liver and kidney function and electrocardiogram monitoring while taking giritinib to ensure the safety of the drug. If there are obvious adverse reactions such as increased creatinine, fatigue, prolongation of QT interval or abnormal liver function, the doctor should be promptly reported for adjustment. In general, a box of giritinib can be taken for about a month at the standard dose. It is a long-term maintenance treatment drug. The regularity and persistence of its medication directly affect the efficacy and survival benefits.

Reference materials:https://www.drugs.com/